Identification
- Generic Name
- Ad5-nCoV
- DrugBank Accession Number
- DB15655
- Background
Ad5-nCoV is a recombinant adenovirus type-5 vector (Ad5) vaccine currently being investigated for prophylaxis against SARS-CoV-2.1,2 It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906)1 with an expected completion in December 2020. The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination.2
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Recombinant - Synonyms
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5AHC3V2UQS
- CAS number
- Not Available
References
- General References
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 4 Completed Prevention Coronavirus Disease 2019 (COVID‑19) 4 4 Not Yet Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 3 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 2 3 Completed Prevention Coronavirus Disease 2019 (COVID‑19) 1 3 Terminated Prevention Coronavirus Disease 2019 (COVID‑19) 1 2 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Covid19, Vaccines 1 2 Completed Prevention Coronavirus Disease 2019 (COVID‑19) 2 2 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 1 Completed Prevention Adenovirus Type-5 Vectored COVID-19 Vaccine / Coronavirus Disease 2019 (COVID‑19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at April 01, 2020 15:23 / Updated at June 12, 2020 16:53